# A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia

> **NCT07243379** · PHASE4 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 495 (estimated)

## Conditions studied

- Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia
- Multicenter Observational Study

## Interventions

- **DRUG:** Nanocrystalline Megestrol Acetate

## Key facts

- **NCT ID:** NCT07243379
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 495 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243379, "A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07243379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*